Can pomegranates prevent prostate cancer? A new study offers promise

September 26, 2005

MADISON - The juice of the pomegranate, say researchers at University of Wisconsin Medical School, shows major promise to combat prostate cancer - the most common invasive cancer and the second-leading cause of cancer death in American men.

With more than 230,000 new cases of prostate cancer expected to be diagnosed this year alone in the U.S. and the outlook poor for patients with metastatic disease, researchers are looking for new strategies to combat the disease. Earlier research at Wisconsin and elsewhere has shown that the pomegranate, a fruit native to the Middle East, is rich in anti-oxidant and anti-inflammatory activity and is effective against tumors in mouse skin. In fact, pomegranate juice has higher anti-oxidant activity than do red wine and green tea, both of which appear promising as anti-cancer agents.

The UW research team aimed to find out if the extract from pomegranates would not only kill existing cancer, but help prevent cancer from starting or progressing. Using human prostate cancer cells, the team first evaluated the fruit extract's effect, at various doses, on those cells cultured in laboratory dishes. They found a "dose-dependent" effect - in other words, the higher the dose of pomegranate extract the cells received, the more cells died.

The research team then progressed to tests in mice that had been injected with prostate cancer cells from humans and developed malignancies. The 24 mice were randomly divided into three groups. The control group received normal drinking water, while the animals in the second and third groups had their drinking water supplemented with .1 percent and .2 percent pomegranate extract respectively. The doses for the mice were chosen to parallel how much pomegranate juice a typical healthy human might be willing to eat or drink daily.

The results were dramatic: the mice receiving the higher concentration of pomegranate extract showed significant slowing of their cancer progression and a decrease in the levels of prostate-specific antigen (PSA), a marker used to indicate the presence of prostate cancer in humans. The animals that received only water had tumors that grew much faster than those in the animals treated with pomegranate extract.

"Our study - while early -- adds to growing evidence that pomegranates contain very powerful agents against cancer, particularly prostate cancer," says lead author Dr. Hasan Mukhtar, professor of dermatology in the UW Medical School. "There is good reason now to test this fruit in humans - both for cancer prevention and for treatment."

The next step in the evaluation of pomegranates for cancer prevention and treatment is to conduct tests in humans, according to Mukhtar.
-end-
The other members of the research team are Arshi Malik, Farrukh Afaq, Vaquar Adhami, Deeba Syed and Sami Sarfaraz, all research scientists in the department of dermatology. The Wisconsin research was funded by the National Institutes of Health.

CONTACT: Lisa Brunette, (608) 263-5830, la.brunette@hosp.wisc.edu

University of Wisconsin-Madison

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.